Structural alterations of the mucosa stroma in the Barrett's esophagus metaplasia-dysplasia-adenocarcinoma sequence

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 9, 2012, Pages 1498-1504

  Bobryshev, Yuri V ^a   Killingsworth, Murray C ^b   Lord, Reginald V N ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b SYDNEY SOUTH WEST AREA HEALTH SERVICE   (Australia)

Author keywords

Barrett's esophagus; Dysplasia; Esophageal adenocarcinoma; Matrix microvesicles; Metaplasia

Indexed keywords

COLLAGEN FIBER;

ARTICLE; BARRET ESOPHAGUS METAPLASIA DYSPLASIA ADENOCARCINOMA SEQUENCE; BARRETT ESOPHAGUS; CAPILLARY; CELL VACUOLE; ELECTRON TOMOGRAPHY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS MUCOSA; EXTRACELLULAR MATRIX; HISTOLOGY; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; STROMA; STROMA CELL; TRANSMISSION ELECTRON MICROSCOPY;

EID: 84865373930     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2012.07179.x     Document Type: Article

References (39)

1. Fléjou JF, Svrcek M. Barrett's oesophagus-a pathologist's view. Histopathology 2007; 50: 3-14.
2. Hornick JL, Odze RD. Neoplastic precursor lesions in Barrett's esophagus. Gastroenterol. Clin. North Am. 2007; 36: 775-96.
3. Tadiparthi R, Bansal A, Sharma P. What's new in columnar lined esophagus (Barrett's metaplasia)? Curr. Opin. Gastroenterol. 2008; 24: 516-20.
4. Yerian L. Histology of metaplasia and dysplasia in Barrett's esophagus. Surg. Oncol. Clin. N. Am. 2009; 18: 411-22.
5. Odze RD. What the gastroenterologist needs to know about the histology of Barrett's esophagus. Curr. Opin. Gastroenterol. 2011; 27: 389-96.
6. Voltaggio L, Montgomery EA, Lam-Himlin D. A clinical and histopathologic focus on Barrett esophagus and Barrett-related dysplasia. Arch. Pathol. Lab. Med. 2011; 135: 1249-60.
7. Xian W, Ho KY, Crum CP, McKeon F. Cellular origin of Barrett's esophagus: controversy and therapeutic implications. Gastroenterology 2012; 142: 1424-30.
8. Phillips WA, Lord RV, Nancarrow DJ, Watson DI, Whiteman DC. Barrett's esophagus. J. Gastroenterol. Hepatol. 2011; 26: 639-48.
9. Jankowski JA, Harrison RF, Perry I, Balkwill F, Tselepis C. Barrett's metaplasia. Lancet 2000; 356: 2079-85.
10. Barbera M, Fitzgerald RC. Cellular origin of Barrett's metaplasia and oesophageal stem cells. Biochem. Soc. Trans. 2010; 38: 370-3.
11. Grotenhuis BA, Dinjens WN, Wijnhoven BP etal. Barrett's oesophageal adenocarcinoma encompasses tumour-initiating cells that do not express common cancer stem cell markers. J. Pathol. 2010; 221: 379-89.
12. Wang X, Ouyang H, Yamamoto Y etal. Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell 2011; 145: 1023-35.
13. Bobryshev YV, Freeman AK, Botelho NK, Tran D, Levert-Mignon AJ, Lord RV. Expression of the putative stem cell marker Musashi-1 in Barrett's esophagus and esophageal adenocarcinoma. Dis. Esophagus 2010; 23: 580-9.
14. von Rahden BH, Kircher S, Lazariotou M etal. LgR5 expression and cancer stem cell hypothesis: clue to define the true origin of esophageal adenocarcinomas with and without Barrett's esophagus? J. Exp. Clin. Cancer Res. 2011; 30: 23.
15. Vega KJ, May R, Sureban SM etal. Identification of the putative intestinal stem cell marker DCAMKL-1 in Barrett's Esophagus and Esophageal Adenocarcinoma. J. Gastroenterol. Hepatol. 2012; 27: 773-80.
16. Nicholson AM, Graham TA, Simpson A etal. Barrett's metaplasia glands are clonal, contain multiple stem cells and share a common squamous progenitor. Gut 2011; PMID: 22200839.
17. Grotenhuis BA, van Lanschot JJ, Dinjens WN, Wijnhoven BP. The pathogenesis of Barrett's metaplasia and the progression to esophageal adenocarcinoma. Recent Results Cancer. Res. 2010; 182: 39-63.
18. Bobryshev YV, Tran D, Killingsworth MC, Buckland M, Lord RV. Dendritic cells in Barrett's esophagus and esophageal adenocarcinoma. J. Gastrointest. Surg. 2009; 13: 44-53.
19. Bobryshev YV, Tran D, Killingsworth MC, Buckland M, Lord RV. Dendritic cell-associated immune inflammation of cardiac mucosa: a possible factor in the formation of Barrett's esophagus. J. Gastrointest. Surg. 2009; 13: 442-50.
20. Bobryshev YV, Lu J, Lord RV. Expression of C1q complement component in Barrett's esophagus and esophageal adenocarcinoma. J. Gastrointest. Surg. 2010; 14: 1207-13.
21. Min KW. Stromal elements for tumor diagnosis: a brief review of diagnostic electron microscopic features. Ultrastruct. Pathol. 2005; 29: 305-18.
22. Provenzano PP, Eliceiri KW, Campbell JM, Inman DR, White JG, Keely PJ. Collagen reorganization at the tumor-stromal interface facilitates local invasion. BMC Med. 2006; 4: 38.
23. Chernov AV, Strongin AY. Epigenetic regulation of matrix metalloproteinases and their collagen substrates in cancer. Biomol. Concepts 2011; 2: 135-47.
24. Abdulghani S, Caetano-Lopes J, Canhão H, Fonseca JE. Biomechanical effects of inflammatory diseases on bone-rheumatoid arthritis as a paradigm. Autoimmun. Rev. 2009; 8: 668-71.
25. Anderson HC, Mulhall D, Garimella R. Role of extracellular membrane vesicles in the pathogenesis of various diseases, including cancer, renal diseases, atherosclerosis, and arthritis. Lab. Invest. 2010; 90: 1549-57.
26. Montoro-García S, Shantsila E, Marín F, Blann A, Lip GY. Circulating microparticles: new insights into the biochemical basis of microparticle release and activity. Basic Res. Cardiol. 2011; 106: 911-23.
27. Porto I, De Maria GL, Di Vito L, Camaioni C, Gustapane M, Biasucci LM. Microparticles in health and disease: small mediators, large role? Curr. Vasc. Pharmacol. 2011; 9: 490-500.
28. Roos MA, Gennero L, Denysenko T etal. Microparticles in physiological and in pathological conditions. Cell Biochem. Funct. 2010; 28: 539-48.
29. Hoyer FF, Nickenig G, Werner N. Microparticles-messengers of biological information. J. Cell. Mol. Med. 2010; 14: 2250-6.
30. Nieuwland R, Sturk A. Why do cells release vesicles? Thromb. Res. 2010; 125 (Suppl. 1): S49-51.
31. Muralidharan-Chari V, Clancy JW, Sedgwick A, D'Souza-Schorey C. Microvesicles: mediators of extracellular communication during cancer progression. J. Cell Sci. 2010; 123 (Pt 10): 1603-11.
32. Nomura S, Ozaki Y, Ikeda Y. Function and role of microparticles in various clinical settings. Thromb. Res. 2008; 123: 8-23.
33. Quesenberry PJ, Aliotta JM. Cellular phenotype switching and microvesicles. Adv. Drug Deliv. Rev. 2010; 62: 1141-8.
34. Al-Nedawi K, Meehan B, Rak J. Microvesicles: messengers and mediators of tumor progression. Cell Cycle 2009; 8: 2014-18.
35. Castellana D, Toti F, Freyssinet JM. Membrane microvesicles: macromessengers in cancer disease and progression. Thromb. Res. 2010; 125 (Suppl. 2): S84-8.
36. Rak J. Microparticles in cancer. Semin. Thromb. Hemost. 2010; 36: 888-906.
37. Valenti R, Huber V, Iero M, Filipazzi P, Parmiani G, Rivoltini L. Tumor-released microvesicles as vehicles of immunosuppression. Cancer Res. 2007; 67: 2912-15.
38. Colleypriest BJ, Ward SG, Tosh D. How does inflammation cause Barrett's metaplasia? Curr. Opin. Pharmacol. 2009; 9: 721-6.
39. Lao-Sirieix P, Fitzgerald RC. Role of the micro-environment in Barrett's carcinogenesis. Biochem. Soc. Trans. 2010; 38: 327-30.